ADC Therapeutics SA (NYSE:ADCT)
$ 2.93 0 (0%) Market Cap: 283.30 Mil Enterprise Value: 107.58 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 45/100

Q3 2022 ADC Therapeutics SA Earnings Call Transcript

Nov 08, 2022 / 01:30PM GMT
Release Date Price: $4.14 (-2.82%)
Operator

Welcome to the ADC Therapeutics Third Quarter 2022 Financial Results Conference Call. My name is Kevin, and I'll be your operator for today's call. (Operator Instructions)

I will now turn the call over to Amanda [Lashpal], Investor Relations Manager. Amanda, you may begin.

Amanda Hamilton
ADC Therapeutics SA - IR Officer

Thank you, operator. This morning, we issued a press release announcing our third quarter 2022 financial results and business updates. This release is available on the ADCT website at ir.adctherapeutics.com under the Press Releases section. On today's call, Ameet Mallik, Chief Executive Officer; Joe Camardo, Chief Medical Officer; and Jen Creel, Chief Financial Officer, will discuss recent business highlights and review our third quarter 2022 financial results before opening the call for questions.

As a reminder, this conference call may contain forward-looking statements. Such statements are subject to risks and uncertainties. For additional information concerning forward-looking statements and factors that could cause

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot